The drug, Carbavance, has already showed promising results for treating melioidosis (Whitmore’s disease) and glanders, two bioterrorism threats that kill up to 90 percent of those exposed. There are current antibiotic treatments for these bacteria, but the mortality rate is still approximately 40 percent for treated patients. Additionally, melioidosis and glanders run the risk of becoming resistant to antibiotics.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Carbavance also has the potential to treat other antibiotic-resistant infections, including urinary tract infections, hospital-acquired pneumonia, ventilator-acquired pneumonia and carbapenem-resistant Enterobacteriaceae.
The five-year agreement included an initial $19.8 million commitment from BARDA, which could extend to a $90 million contribution over the course of the agreement.
More Articles on Drug-Resistant Bacteria:
MRSA Drug Dosage Calculations Inaccurate for Teenagers
Researchers Develop Test for Super-Virulent C. diff Strains
Advocate Lutheran General CRE Outbreak Largest in U.S.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
